Drug Maker Launches Treatment For Drug-Resistant Malaria
Novartis is taking aim at drug-resistant by launching clinical trials of the first new antimalarial medicine for many years in nine countries across Africa and Asia. The Swiss drug maker, which is working on the mid-stage Phase IIb trial program with the group Medicines for Malaria Venture (MMV), said on Monday it believed its drug KAF156 could be a "game-changer".

